WO2004084822A3 - Methods for inducing immune tolerance - Google Patents

Methods for inducing immune tolerance Download PDF

Info

Publication number
WO2004084822A3
WO2004084822A3 PCT/US2004/008500 US2004008500W WO2004084822A3 WO 2004084822 A3 WO2004084822 A3 WO 2004084822A3 US 2004008500 W US2004008500 W US 2004008500W WO 2004084822 A3 WO2004084822 A3 WO 2004084822A3
Authority
WO
WIPO (PCT)
Prior art keywords
lir
infectious diseases
susceptibility
gene expression
expression
Prior art date
Application number
PCT/US2004/008500
Other languages
French (fr)
Other versions
WO2004084822A2 (en
Inventor
Robert L Modlin
Joshua R Bleharski
Marco Collonna
Original Assignee
Iniversity Of California
Robert L Modlin
Joshua R Bleharski
Marco Collonna
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iniversity Of California, Robert L Modlin, Joshua R Bleharski, Marco Collonna filed Critical Iniversity Of California
Publication of WO2004084822A2 publication Critical patent/WO2004084822A2/en
Publication of WO2004084822A3 publication Critical patent/WO2004084822A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily

Abstract

The regulatory mechanisms that influence resistance versus susceptibility to progressive infection by microbial pathogens are of fundamental importance to understanding pathogenesis and to developing effective vaccines. Susceptibility to progressive infection in the lepromatous form correlated with the local expression of genes encoding members of the leukocyte immunoglobulin-like receptor (LIR) family, including LIR-3, -4, -7, and - 8. The gene expression profiles provided a clear and consistent distinction between the different clinical courses of the disease. The present invention shows that gene expression technology may be useful for predicting the clinical course of leprosy and perhaps other infectious diseases. Further, the invention provides methods of treatment of inflammatory or infectious diseases based on regulation of LIR-7 expression or activity.
PCT/US2004/008500 2003-03-21 2004-03-19 Methods for inducing immune tolerance WO2004084822A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45678903P 2003-03-21 2003-03-21
US60/456,789 2003-03-21

Publications (2)

Publication Number Publication Date
WO2004084822A2 WO2004084822A2 (en) 2004-10-07
WO2004084822A3 true WO2004084822A3 (en) 2007-02-01

Family

ID=33098156

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/008500 WO2004084822A2 (en) 2003-03-21 2004-03-19 Methods for inducing immune tolerance

Country Status (1)

Country Link
WO (1) WO2004084822A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11894121B2 (en) 2021-08-06 2024-02-06 Reviv Global Ltd Prescriptive nutrition-based IV and IM infusion treatment formula creation systems and methods
US11600375B2 (en) 2021-07-30 2023-03-07 Reviv Global Ltd Genetically personalized food recommendation systems and methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6517839B1 (en) * 1997-07-18 2003-02-11 The Regents Of The University Of California Methods for inducing interleukin-12 and a type1/Th1 T-cell response
US6562343B1 (en) * 1995-03-03 2003-05-13 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562343B1 (en) * 1995-03-03 2003-05-13 Millennium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of immune disorders
US6517839B1 (en) * 1997-07-18 2003-02-11 The Regents Of The University Of California Methods for inducing interleukin-12 and a type1/Th1 T-cell response

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
TEDLA N. ET AL.: "Activation of Human eosinophils through leukocyte immunoglobulin-like receptor 7", PNAS, vol. 100, no. 3, February 2003 (2003-02-01), pages 1174 - 1179, XP003007014 *
TEDLA N. ET AL.: "The co-expression of activating and inhibitory leukocyte immunoglobulin-like receptors in rheumatoid synovium", AM. J. PATH., vol. 160, no. 2, February 2002 (2002-02-01), pages 425 - 431, XP002966652 *

Also Published As

Publication number Publication date
WO2004084822A2 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
Yang et al. The signal pathways and treatment of cytokine storm in COVID-19
Pillai et al. Mx1 reveals innate pathways to antiviral resistance and lethal influenza disease
Lidbury et al. Macrophage-derived proinflammatory factors contribute to the development of arthritis and myositis after infection with an arthrogenic alphavirus
Raison et al. The evolutionary significance of depression in Pathogen Host Defense (PATHOS-D)
Lotrich et al. Depression following pegylated interferon-alpha: characteristics and vulnerability
Li et al. Artemisinin analogue SM934 ameliorates murine experimental autoimmune encephalomyelitis through enhancing the expansion and functions of regulatory T cell
PL1693064T3 (en) Treating weight loss in patients suffering from inflammatory bowel diseases with S. boulardii
JP2016523862A5 (en)
ATE551350T1 (en) METHODS AND REAGENTS FOR THE TREATMENT AND DIAGNOSIS OF VASCULAR DISEASES AND AGE-RELATED MACULAR DEGENERATION
SG156625A1 (en) Method for measuring resistance or sensitivity to docetaxel
WO2008137762A3 (en) Methods of diagnosis and treatment of crohn's disease
Tripathi et al. Type 1 interferon mediates chronic stress-induced neuroinflammation and behavioral deficits via complement component 3-dependent pathway
WO2008014400A3 (en) Crohn disease susceptibility gene
Huang et al. Expression of toll-like receptors and type 1 interferon specific protein MxA in biliary atresia
Li et al. Cerebrospinal fluid Th1/Th2 cytokine profiles in children with enterovirus 71‐associated meningoencephalitis
WO2004084822A3 (en) Methods for inducing immune tolerance
Jonas et al. Long-term growth outcomes in children treated for chronic hepatitis C
Nguyen et al. Treatment eligibility of patients with chronic hepatitis B initially ineligible for therapy
Koriem Corrigendum to ‘Multiple sclerosis: New insights and trends’
de Souza et al. Concurrent gastro-intestinal nematode infection does not alter the development of experimental cerebral malaria
DE602004029331D1 (en) DEFENSINPROTEINE
UA86750C2 (en) Use of il-1f7b, able to bind il-18r and il-18bp, with il-18bp for the treatment of diseases associated with excessive il-18activity
Kenan et al. Reasons for delayed treatment initiation in Guillain-Barre syndrome
Alexander et al. Can type-1 responses against intracellular pathogens be T helper 2 cytokine dependent?
WO2006006853A3 (en) Differences in intestinal gene expression profiles

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase